NextCell Pharma
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million
REG
The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's website, www.nextcellpharma.com, and Redeye's website, www.redeye.se, and will be available on the Swedish Financial Supervisory Authority's website, www.fi.se.
Timetable for the Rights Issue
| 31 May - 11 June 2024 | Trading in unit rights on Nasdaq First North Growth Market |
| 31 May - 14 June 2024 | Subscription period in the Rights Issue |
| 31 May 2024 - Until the Rights Issue is registered by the Swedish Companies Registration Office | Trading in paid subscribed units on Nasdaq First North Growth Market |
| Around 18 June 2024 | Expected day for announcement of the outcome |
Advisors
Redeye AB is financial advisor to NextCell in connection with the Rights Issue. Törngren Magnell & Partners Advokatfirma KB is legal advisor to the Company in connection with the Rights Issue.
| Datum | 2024-05-30, kl 13:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!